Background: Thoracic aortic mural thrombus (TAMT) of the descending aorta is rare but can result in dramatic embolic events. Early treatment is therefore crucial; however, there is not a consensus on ideal initial treatment.
Peripheral arterial emboli are most often cardiac in origin, with other recognized sources originating in the atherosclerotic or aneurysmal aorta. 1, 2 Thoracic aortic mural thrombus (TAMT), characterized by sessile or pedunculated aortic thrombi that develop in the absence of pre-existing aortic disease, is an uncommon pathologic process with potentially devastating complications. Autopsy reports quote a 0.45% incidence in the general population, with 17% showing evidence of distal embolization and 6% severe enough to be considered the cause of death. 3 As this remains a relatively rare disease, there is no consensus on the nature of disease, prognostic assessments, or optimal treatment strategy. Treatment strategies span medical management with anticoagulation alone to more invasive measures, including open thrombectomy, surgical replacement, and endovascular exclusion. Given the relatively small number of case reports and reviews, the best management strategy for a symptomatic TAMT is not well established. The primary objective of this review was to examine common management strategies and outcomes reported in recent cases within the descending thoracic aorta.
METHODS
An extensive review of the literature was conducted, and all relevant publications describing TAMT of the past 15 years were reviewed by two independent reviewers. Publications were found using a PubMed search with phrases including "aortic mural thrombus," "thoracic aortic thrombus," "mural thrombi," and various combinations of these. Relevant sources cited within pertinent papers were also reviewed. Cases describing concurrent aortic or cardiac diseases, such as aneurysm, penetrating aortic ulcer, severe atherosclerosis, calcification of the thoracic aortic wall, aortic sarcoma, or intracardiac thrombus, were excluded. Cases describing thrombus located in the ascending aorta, abdominal aorta, or aortic arch were also excluded. Thirty-two publications were found describing descending TAMT, with 74 patients included in this analysis. 1, There were 26 single case reports and case series with up to 10 patients reported. As the depth of variables presented with each case report or series varied, we specifically looked at the presentation, initial treatment strategy employed, outcome measures of thrombus resolution or regression, recurrence of symptomatic emboli, and mortality.
RESULTS
Female patients were significantly more likely to present with TAMT than male patients in the cases reviewed (43 vs 23; P < .01). The median age of patients was 54.2 years (total range, 28-84 years). The distribution of ages was similar in men and women (Table I ). Most cases (82.4%) reported were diagnosed after an embolic event, the majority (56.8%) being emboli to the lower extremities (Fig 1) . Three patients presented with cerebral emboli and one patient presented with upper extremity emboli; whereas the TAMT in these cases was identified distal to the left subclavian artery, they represented cases of particularly large and mobile thrombus. There was no difference in mortality within patients presenting with visceral vs lower extremity emboli (8.3% and 9.5%, respectively). Table II and Fig 2 demonstrate outcomes of initial treatment strategies and alternative treatment modalities after failed initial therapy. Failure of medical management was most frequently defined by persistent thrombus with recurrent embolization; in one case, there was enlargement of a highly mobile thrombus. Of patients who initially underwent medical management, nine patients (34.6%) had persistent thrombus. Medical therapy was found to be more likely associated with persistent thrombus compared with open thrombectomy or thoracic endovascular aortic repair (TEVAR; P < .05). Of these, three had fatal embolic events and one had a complex medical history resulting in cardiac arrest during her hospitalization. Four patients who failed to respond to medical management subsequently underwent endovascular repair; of note, two of these patients had the thrombus identified incidentally, and one suffered renal artery embolism while receiving anticoagulation. 4 Failure of medical management was defined by recurrent embolization or enlargement of the thrombus. TEVAR after failed medical management was primarily described in one series. 3 All patients in this series initially received full, systemic anticoagulation with heparin for 2 weeks. Indications for TEVAR included renal emboli (despite initial asymptomatic discovery), recurrent emboli in two patients, and presence of a highly mobile, large thrombus in the fourth patient. TEVAR is increasingly being used as the initial treatment strategy (39.2%), as found in recent reports (Table III ; P < .05 for TEVAR use in the last 5 years). However, medical management with anticoagulation (35.1%) and open surgical treatment (25.7%) are also frequently employed in patients presenting with TAMT. In the cases reviewed, men and women were equally likely to initially receive medical management, open surgery, or TEVAR (Table I) . Patients initially undergoing TEVAR were significantly older than patients initially treated with medical management or open surgery (62 years vs 48.5 years and 50 years, respectively; P < .01; Table I ). Of note, there was no significant difference in age between patients initially treated with medical management and those treated with open surgery.
Of the patients who initially underwent open surgical repair, the majority (16 patients) underwent direct thrombectomy. Two patients underwent aortic replacement with graft and one patient underwent thrombectomy with Dacron patch placement. Six patients (31.6%), all within the thrombectomy group, had persistent thrombus; of these patients, four underwent endovascular repair. Of the patients who went on to endovascular repair, three patients had recurrent thrombi with recurrent emboli, and one patient had recurrent thrombus at the site of thrombectomy, increased in size from original, 1 month after extraction. Patients who received TEVAR after initial failed medical management or open surgery had resolution of their thrombus at follow-up.
Twenty-nine patients (39.2%) with descending TAMT initially underwent TEVAR. Twenty-seven (93.1%) had fully excluded thrombus at the time of the procedure with no recurrence or evidence of repeated embolic phenomena at follow-up. Two patients died after TEVAR in the perioperative period; one patient had polycythemia vera and developed a massive thromboembolic phenomenon during his hospitalization, and the other patient developed acute renal failure and pulmonary distress in the immediate postoperative period. No reports of reaccumulation of thrombus within the graft were reported in the literature, with an average follow-up time of 18 months.
DISCUSSION
Aortic mural thrombus in the absence of atherosclerotic occlusive or aneurysmal disease is a relatively uncommon entity. Multiple causes and risk factors for TAMT have been described, including hypercoagulable states (including nonaortic malignant disease), smoking, steroid use, trauma, drug abuse, heparin-induced it is a significant source of noncardiogenic emboli with a difficult diagnosis and a high rate of complications, including end-organ damage, acute limb ischemia, and high mortality. The most common location for aortic mural thrombi is within the descending aorta (37.5%), 33 and more than one treatment strategy may be required. The best management for patients with TAMT is not well established in the literature. Recurrence of aortic thrombi in patients receiving medical therapy alone ranges from 0% to 50% in limited series. 32, 34, 35 In this series, we have observed a 34.6% persistence rate in patients undergoing medical therapy with anticoagulation. Most of the patients who failed to respond to medical therapy had recurrent emboli events within 2 to 4 weeks after initializing therapy. Whereas some authors suggest using anticoagulation as monotherapy, given the potentially devastating outcome of recurrent embolic events, it would seem prudent to reserve medical management for patients in whom surgical therapy is not feasible, such as active infection or patients with severe ongoing medical conditions. It is also essential to select compliant patients in using medical therapy as these patients need frequent and reliable follow-up to manage their oral anticoagulation. Patients who were successfully managed medically were generally prescribed therapeutic anticoagulation until complete resolution of their thrombus, typically within 4 to 12 months. In addition, the role of medical therapy as an adjuvant to surgical intervention has traditionally been determined on an individualized basis. A number of reports endorse the use of continued oral anticoagulation after either open surgical repair or TEVAR. 7, 10, 12, 16, 18, 22, 23, 25, 29, 30, 36 Some of these decisions may have been based on the desire to protect the distal vascular territory that was damaged by prior emboli and directly related to TEVAR placement. Thus, it is unclear whether the perceived success of surgical therapy is dependent on adjuvant medical therapy. In patients with embolic events and a large clot burden, open aortic surgery by thrombectomy, aortic endarterectomy, or replacement can be considered. Recurrent thrombus appeared only in patients who underwent thrombectomy alone, and patients undergoing open surgical therapy have the added morbidity associated with thoracotomy. Interestingly, our series review suggested that these open surgical patients are no less likely to develop recurrent thrombi than patients treated with anticoagulation alone. However, open surgical therapy may be considered the appropriate initial treatment strategy in a select group of patients, such as when there is a substantial clot burden that would require extensive coverage or result in a high risk of embolization if treated solely with endovascular therapy. Aortic replacement or endarterectomy is an appealing first approach in younger patients with no medical comorbidities. Thrombectomy alone, however, seems to be limited in efficacy.
TEVAR for mural thrombi of the descending aorta was first described in 2004. 7 Since then, endovascular repair has been increasingly described to treat TAMT. Endovascular repair has the advantage of being minimally invasive, low risk, and a successful definitive therapy for TAMT. In small series, there has been no difference in the outcomes between stent graft and bare-metal stent implantation. 24 Whereas an endovascular approach to excluding descending TAMT potentially risks repeated distal embolization during wire manipulation and stent graft deployment, no such reports have been described in the literature. Furthermore, some authors suggest the use of certain techniques to avoid such complications, such as aortography through a subclavian approach to visualize the thrombus shadow, intravascular ultrasound, temporary balloon occlusion of selected visceral vessels, and a seal zone at least 2 cm proximal and distal to the thrombus. 24, 25, 32, 37 It is unclear whether the lack of reported embolic phenomena is a result of selection bias in that TEVAR was reserved for patients with favorable anatomy and a smaller area of coverage required, whereas patients with a large clot burden were initially selected to undergo a trial of medical management in an attempt to reduce their clot burden or were determined to be candidates for open surgical repair. It is clear, however, that TEVAR has been beneficial for patients in a variety of scenarios and can be used successfully for high-risk patients with aortic thrombus presenting with embolization, symptomatic patients, patients with recurrent embolization, and patients who have a contraindication to or are unresponsive to anticoagulant therapy. Endovascular stent graft exclusion seems to be an effective option with low morbidity and mortality, and it is effective for both failed medical and open surgical therapy. There is a need for more detailed studies and better follow-up regarding the use of TEVAR for TAMT to report on the durability of results from such a treatment modality.
Limitations. Clearly, it would be advantageous to have larger prospective studies examining medical, surgical, Statistical analysis with c and endovascular treatment of TAMT to further determine whether TEVAR is distinctly superior to medical or open surgical treatment. Given the rarity of this pathologic process, it is unlikely that such a study will occur.
CONCLUSIONS
Although TAMT is uncommon, it must be considered in the differential diagnosis of embolic events. The mortality and recurrent thrombus formation call into question the usefulness of open surgical treatment over medical therapy; however, for young patients, a trial of anticoagulation followed by either open or endovascular treatment may be effective. Endovascular therapy undoubtedly relies on suitable anatomy without prohibitive clot burden, and in this series, it effectively treated patients for whom open surgery and medical therapy failed. Although endovascular therapy may be a useful first-line option for TAMT, further study of this treatment option would be useful for long-term outcome. 
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